Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Philips picks up airway clearance device dev RespirTech
Royal Philips said today it inked a deal to acquire airway clearance solution developer RespirTech for an undisclosed amount.
St. Paul, Minn.-based RespirTech was founded in 2004 and has approximately 210 employees. The company produces airway clearance devices for patients with chronic respiratory conditions, such as chronic obstructive pulmonary disease and cystic fibrosis. Read more
4. Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo
Otsuka Pharmaceutical and Proteus Digital Health said today that the FDA accepted its resubmitted new drug application for their “smart pill”. The drug-device product combines Abilify and a Proteus ingestible sensor in a single tablet.
The FDA is slated to make a decision on the NDA resubmission in the 4th quarter this year. Read more
3. Anaconda Biomed raises $17m for next-gen brain thrombectomy device
Anaconda Biomed said it raised nearly $17 million (€15 million) in a Series A round for the neurothrombectomy device it’s developing.
The round, led by new investors Ysios Capital, Omega Funds and Banco Sabadell and prior backer Innogest Capital, is enough to carry the ANCD Brain device through validation & verification and clinical studies ahead of a CE Mark bid in the European Union, co-founder & CEO Ofir Arad said in prepared remarks. Read more
2. Bain Capital raises $720m life sciences fund
Bain Capital said today that it raised $720 million for its 1st investment fund focused exclusively on the life sciences sector.
“We are excited by some of the long-term secular trends in the life sciences space,” Bain Capital Life Sciences managing director Adam Koppel said. “Big pharma is increasingly outsourcing R&D at the same time as many new technologies and treatments are being developed.” Read more
1. EnteroMedics jumps pre-market on BarioSurg buyout
EnteroMedics said today that it acquired BarioSurg and the gastric vest it developed to treat obesity, sending share prices surging in pre-market trading.
The BarioSurg device is designed to be implanted via laparoscopy to wrap the stomach and emulate the effects of conventional bariatric surgery by temporarily reducing the stomach’s volume. Read more
